Immunohistochemistry-based molecular subtypes and stromal tumor-infiltrating lymphocytes in triple-negative breast cancer: a chemotherapy-only cohort
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag322 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Jesus Edgardo Hernandez-Hernandez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, 64710, Mexico. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Lymphocytes, Tumor-Infiltrating, Biomarkers, Tumor. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Triple-negative breast cancer (TNBC) is a biologically heterogeneous, aggressive disease where immunohistochemistry (IHC)-based algorithms, defining luminal androgen receptor (LAR), immunomodulatory (IM), basal-like immunosuppressed (BLIS), mesenchymal (MES), and unclassifiable (UC) subtypes, offer a pragmatic alternative to transcriptomics. This study evaluated clinical trajectories and survival outcomes associated with IHC-based molecular subtypes and stromal tumor-infiltrating lymphocytes (sTILs) across distinct subgroups.
Methods
A retrospective analysis of 289 women with TNBC treated with chemotherapy-only regimens analyzed molecular subtypes across four clinical groups: non-recurrent, recurrent, progression during neoadjuvant chemotherapy, and de novo metastatic disease. IHC-based subclassification included androgen receptor (AR), CD8, FOXC1, and DCLK1 biomarkers. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method, and multivariable Cox proportional hazards models.
Results
The cohort included non-recurrent (43.9%), recurrent (26.3%), neoadjuvant progressors (11.5%), and de novo stage IV (18.3%) cases. IM subtype (16.3%) was enriched in non-recurrent cases with the highest median sTILs levels (20.0%). BLIS (26.3%) and UC (39.4%) subtypes predominated in recurrent and metastatic disease, while MES subtype (9.0%) predominated in neoadjuvant chemotherapy progressors. In early-stage disease, sTILs ≥10% independently predicted superior OS (HR 0.63, 95% CI, 0.40-1.0; P = .049), showing no prognostic role in the de novo stage IV group. Molecular subtypes lost independent significance in multivariable models.
Conclusions
Clinicopathological factors and sTILs remain primary prognostic determinants in TNBC. Although IHC-based molecular subtypes were not independent survival predictors, their differential clinical distribution validates their biological relevance to identify therapeutic vulnerabilities, and to guide precision medicine and de-escalation strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, 64710, Mexico.
- Oncology Institute and Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza Garcia, 66278, Mexico.
- Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología e Instituto de Investigaciones Biomédicas, UNAM, Mexico City, 14080, Mexico.
- Subdirección de Patología, Instituto Nacional de Cancerología, Mexico City, 14080, Mexico.
- Division of Oncology and Hematology, Instituto Nacional de Cancerología, Mexico City, 14080, Mexico.
- Facultad de Medicina y Hospital Universitario "Dr José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, 64460, México.
ORCID-Profile: Jesus Edgardo Hernandez-Hernandez, Paula Cabrera-Galeana, Gabriela Sofía Gómez-Macías, Cynthia Villarreal-Garza
Zitieren
APA
Hernandez-Hernandez, J. E., Mohar, A., Lara-Torres, C. O., Vazquez-Juarez, D., Palacios, T., Peña-Torres, L., Moncada-Claudio, G., Velazquez-Martinez, A., Cabrera-Galeana, P., Gómez-Macías, G. S., Porras-Reyes, F. I., Pérez-Sánchez, V. M., Aranda-Gutierrez, A., & Villarreal-Garza, C. (2026). Immunohistochemistry-based molecular subtypes and stromal tumor-infiltrating lymphocytes in triple-negative breast cancer: a chemotherapy-only cohort. The Oncologist. https://doi.org/10.1093/oncolo/oyag322
Vancouver
Hernandez-Hernandez JE, Mohar A, Lara-Torres CO, Vazquez-Juarez D, Palacios T, Peña-Torres L, et al. Immunohistochemistry-based molecular subtypes and stromal tumor-infiltrating lymphocytes in triple-negative breast cancer: a chemotherapy-only cohort. The Oncologist. 2026. doi:10.1093/oncolo/oyag322
BibTeX
@article{HernandezHernandez2026,
author = {Hernandez-Hernandez, Jesus Edgardo and Mohar, Alejandro and Lara-Torres, César Octavio and Vazquez-Juarez, Daniela and Palacios, Tamara and Peña-Torres, Lourdes and Moncada-Claudio, Guadalupe and Velazquez-Martinez, Areli and Cabrera-Galeana, Paula and Gómez-Macías, Gabriela Sofía and Porras-Reyes, Fany Iris and Pérez-Sánchez, Víctor Manuel and Aranda-Gutierrez, Alejandro and Villarreal-Garza, Cynthia},
title = {Immunohistochemistry-based molecular subtypes and stromal tumor-infiltrating lymphocytes in triple-negative breast cancer: a chemotherapy-only cohort},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag322}
}
EUVIMED